News Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:42:43 2025-12-10 pm EST			5-day change	1st Jan Change
165.19 ^USD	+1.81%		-1.53%	+33.62%

08:58am	This Is Decision Day
05:51am	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…

This Is Decision Day	08:58am
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…	05:51am
Jazz Pharmaceuticals Insider Sold Shares Worth $797,783, According to a Recent SEC Filing	Dec. 09	MT
Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting	Dec. 05	CI
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting	Dec. 05	PR
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium	Dec. 02	PR
Jazz Pharmaceuticals plc to Present Pivotal Phase 3 Results of Ziihera®? (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCOGastrointestinal Cancers Symposium	Dec. 02	CI
Jazz Pharmaceuticals plc Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09:45 AM	Dec. 02
Jazz Pharmaceuticals Insider Sold Shares Worth $13,780,337, According to a Recent SEC Filing	Dec. 02	MT
Stockholm Bullets – Arise Soars on Takeover Bid	Nov. 27	FW
Saniona Reports Operating Profit of SEK 360 Million	Nov. 27	FW
Saniona publishes its interim report for the third quarter of 2025	Nov. 27	AQ
Jazz Pharmaceuticals Insider Sold Shares Worth $607,127, According to a Recent SEC Filing	Nov. 24	MT
Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says	Nov. 24	MT
UBS Downgrades Jazz Pharmaceuticals to Neutral From Buy, Raises Price Target to $188 From $163	Nov. 24	MT
Jazz Pharmaceuticals Insider Sold Shares Worth $3,259,538, According to a Recent SEC Filing	Nov. 21	MT
Jazz Pharmaceuticals : Partial Redemption of Jazz Pharmaceuticals UK Holding Limited	Nov. 20	PU
Jazz Pharmaceuticals Insider Sold Shares Worth $1,204,573, According to a Recent SEC Filing	Nov. 20	MT
Truist Adjusts Price Target on Jazz Pharmaceuticals Public to $220 From $205, Maintains Buy Rating	Nov. 19	MT
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference	Nov. 18	PR
Traders Strap In, Again	Nov. 18
Deutsche Bank Raises Price Target on Jazz Pharmaceuticals to $210 From $173, Keeps Buy Rating	Nov. 18	MT
Analyst recommendations: Alphabet, Amazon, Microsoft, AbbVie, Comcast…	Nov. 18
Zymeworks Commences Strategic Initiative for Licensed Products to Enhance Future Cash Flows	Nov. 18	MT
Top Midday Gainers	Nov. 17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Filters